Effects of functionalized silver nanoparticles on aggregation of human blood platelets

References

• Lee SH, Jun BH. Silver nanoparticles: synthesis and application for nanomedicine. Int J Mol Sci. 2019;20:4.
   Web of Science ®Google Scholar
• Rai M, Kon K, Ingle A, Duran N, Galdiero S, Galdiero M. Broad-spectrum bioactivities of silver nanoparticles: the emerging trends and future prospects. Appl Microbiol Biotechnol. 2014;98(5):1951–1961. doi:10.1007/s00253-013-5473-x24407450
   PubMed Web of Science ®Google Scholar
• Pudlarz A, Szemraj J. Nanoparticles as carriers of proteins, peptides and other therapeutic molecules. Open Life Sci. 2018;13:285–298. doi:10.1515/biol-2018-0035
   PubMed Web of Science ®Google Scholar
• Santos-Martinez MJ, Rahme K, Corbalan JJ, et al. Pegylation increases platelet biocompatibility of gold nanoparticles. J Biomed Nanotechnol. 2014;10(6):1004–1015.24749395
   PubMed Web of Science ®Google Scholar
• Huang H, Wenija L, Menghua C. An evaluation of blood compatibility of silver nanoparticles. Sci Rep. 2016;6(255180):1–15.28442746
   PubMedGoogle Scholar
• Jun EA, Lim KM, Kim KY. Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. Nanotoxicology. 2011;5(2):157–167. doi:10.3109/17435390.2010.50625020822370
   PubMed Web of Science ®Google Scholar
• Shrivstava S, Singh S, Mukhopadhyay A. Negative regulation of fibrin polymerization and clot formation by nanoparticles of silver. Colloids Surf B. 2011;82(1):241–246. doi:10.1016/j.colsurfb.2010.08.048
   PubMed Web of Science ®Google Scholar
• Ragaseema VM, Unnikrishnan S, Kalliyana Krishnan V, Krishnan LK. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. Biomaterials. 2012;33(11):3083–3092. doi:10.1016/j.biomaterials.2012.01.00522284585
   PubMed Web of Science ®Google Scholar
• Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger DW, Munger MA. Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanotoxicology 2014;8(3):328–333.
   Google Scholar
• Thasneem YM, Sajeesh S, Sharma C. Effect of thiol functionalization on the hemo‐compatibility of PLGA nanoparticles. J Biomed Mater Res. 2011;99A(4):607–617. doi:10.1002/jbm.a.33220
   Web of Science ®Google Scholar
• Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011;6(4):71. doi:10.2217/nnm.11.19
   Web of Science ®Google Scholar
• Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–627. doi:10.1038/nrd259120616808
   PubMed Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 2012;13(1):105–119. doi:10.2174/13892001279835693421892917
   PubMed Web of Science ®Google Scholar
• Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114(3):343–347. doi:10.1016/j.jconrel.2006.06.00116876898
   PubMed Web of Science ®Google Scholar
• Nguyen KC, Seligy VL, Massarsky A, et al. Comparison of toxicity of uncoated and coated silver nanoparticles. J Phys. 2013;429:1–15.
   Google Scholar
• Niska K, Knap N, Kędzia A, Jaskiewicz M, Kamysz W, Inkielewicz-Stepniak I. Capping agent-dependent toxicity and antimicrobial activity of silver nanoparticles: an in vitro study. Concerns about potential application in dental practice. J Med Sci. 2016;13(10):772–782.
   Google Scholar
• Chen Y, Wang X. Novel phase-transfer preparation of monodisperse silver and gold nanoparticles at room temperature. Mater Lett. 2008;62(15):2215–2218. doi:10.1016/j.matlet.2007.11.050
   Google Scholar
• Van der Linden M, Barendregt A, van Bunningen AJ. Characterisation, degradation and regeneration of luminescent Ag29 clusters in solution. Nanoscale. 2016;8(47):19901–19909. doi:10.1039/C6NR04958C27878182
   PubMedGoogle Scholar
• Radomski MW, Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb Res. 1983;30:383–389. doi:10.1016/0049-3848(83)90230-X6351341
   PubMed Web of Science ®Google Scholar
• Santos-Martinez MJ, Inkielewicz-Stepniak I, Medina C, et al. The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation. Int J Nanomedicine. 2012;7:243–255. doi:10.2147/IJN.S3063122275839
   PubMed Web of Science ®Google Scholar
• Santos-Martinez MJ, Tomaszewski KA, Medina C, Bazou D, Gilmer JF, Radomski MW. Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry. Int J Nanomedicine. 2015;10:5107–5119.26316743
   PubMed Web of Science ®Google Scholar
• Niles AL, Moravec RA, Riss TL. In vitro and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening. Curr Chem Genomics. 2009;3:33–41. doi:10.2174/187539730090301003320161834
   PubMedGoogle Scholar
• Xu X, Gao X, Pan R, Lu D, Dai Y. A simple adhesion assay for studying interactions between platelets and endothelial cells in vitro. Cytotechnology. 2010;61(1):17–22. doi:10.1007/s10616-010-9256-2
   Google Scholar
• Ka-Ming Chan F, Moriwaki K, De Rosa MJ. Detection of necrosis by release of lactate dehydrogenase 9LDH) activity. Methods Mol Biol. 2013;979:65–70.23397389
   PubMedGoogle Scholar
• Laloy J, Minet V, Alpan L. Impact of Silver nanoparticles on haemolysis, platelet function and coagulation. Nanobiomedicine. 2014;1:4. doi:10.5772/5934630023015
   PubMedGoogle Scholar
• Zielinska E, Tukaj C, Radomski MW, Inkielewicz-Stepniak I. Molecular mechanism of silver nanoparticles-induced human osteoblast cell death: protective effect of inducible nitric oxide synthase inhibitor. PLoS One. 2016;11(10):e0164137. doi:10.1371/journal.pone.016413727716791
   PubMedGoogle Scholar
• Stoehr LC, Gonzalez E, Stampfl A, et al. Shape matters: effects of silver nanospheres and wires on human alveolar epithelial cells. Part Fibre Toxicol. 2011;8:36. doi:10.1186/1743-8977-8-3622208550
   PubMed Web of Science ®Google Scholar
• Helmlinger J, Sengstock C, Groß-Heitfeld C. Silver nanoparticles with different size and shape: equal cytotoxicity, but different antibacterial effects. RSC Adv. 2016;6:18490–18501. doi:10.1039/C5RA27836H
   Web of Science ®Google Scholar
• Inkielewicz-Stepniak I, Santos-Martinez MJ, Medina C, Radomski MW. Pharmacological and toxicological effects of co-exposure of human gingivial fibroblasts to silver nanoparticles and sodium fluoride. Int J Nanomedicine. 2014;2(9):1677–1687.
   Google Scholar
• Peng Y, Song C, Yang C, Guo Q. Low molecular weight chitosan-coated silver nanoparticles are effective for the treatment of MRSA-infected wounds. Int J Nanomedicine. 2017;12:295–304. doi:10.2147/IJN.S12235728115847
   PubMedGoogle Scholar
• López I.A., Ceballos M., Hernández G., Acosta L., Gómez I., Shape transformation from silver triangular nanoprisms to nanodisks: Raman characterization and sculpturing mechanism. Revista Mexicana de Fisica. 2015;61(2):77–82.
   Google Scholar
• Suk JS, Xu Q, Kim N, Hanes J, Ensign LM, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51. doi:10.1016/j.addr.2015.09.012
   PubMedGoogle Scholar
• Liang C, Shangchun L, Xiaochun G, Ping X, Jun C. The role of GSH in microcystin‐induced apoptosis in rat liver: involvement of oxidative stress and NF-κB. Environ Toxicol. 2016;31(5):552–560.25410294
   PubMed Web of Science ®Google Scholar
• Li H, Cui Z, Han C. Glutathione-stabilized silver nanoparticles as colorimetric sensor for Ni2+ ion. Sensor Actuat B-Chem. 2009;143(1):87–92. doi:10.1016/j.snb.2009.09.013
   Web of Science ®Google Scholar
• Silvan JM, Zorraguin–Pena I, Gonzalez de Llano D, Moreno-Arribas MV, Martinez-Rodriguez AJ. Antibacterial activity of glutathione-stabilized silver nanopartciles against Campylobacter multidrug –resistant strains. Front Micorbiol. 2018;9:458. doi:10.3389/fmicb.2018.00458
   PubMed Web of Science ®Google Scholar
• Zabielska-Koczywas K, Dolka I, Król M, et al. Doxorubicin conjugated to glutathione stabilized gold nanopartciles (Au-GSH-Dox) a s an effective therapeutic agent for feline injection-site Sarcomas-chick embryo chorioallantoic membrane study. Molecules. 2017;22(2):253. doi:10.3390/molecules22020253
   PubMed Web of Science ®Google Scholar
• Turcu I, Zarafu I, Popa M, et al. Lipoic acid gold nanopartciles functionalized with organic compounds as bioactive materials. Nanomaterials. 2017;7(2):43. doi:10.3390/nano7120458
   Web of Science ®Google Scholar
• Kim YS, Kim JS, Cho HS, et al. Twenty-eight day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in sprague-dawley rats. Inhal Toxicol. 2008;20:575–583. doi:10.1080/0895837070186151218444010
   PubMed Web of Science ®Google Scholar
• Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano. 2009;3(6):1357–1364. doi:10.1021/nn900784f19545167
   PubMed Web of Science ®Google Scholar
• Krishnaraj RN, Berchmans S. In vitro antiplatelet activity of silver nanoparticles synthesized using the microorganism Gluconobacter roseus: an AFM-based study. RSC Adv. 2013;3:8953–8959. doi:10.1039/c3ra41246f
   Web of Science ®Google Scholar
• Tomaszewski KA, Radomski MW, Santos-Martinez MJ. Nanodiagnostics, nanopharmacology and nanotoxicology of platelet-vessel wall interactions. Nanomedicine (Lond). 2015;10(9):1451–1475. doi:10.2217/nnm.14.8625996119
   PubMed Web of Science ®Google Scholar
• Radomski A, Jurasz P, Sander EJ, et al. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol. 2002;137(8):1330–1338. doi:10.1038/sj.bjp.070484012466243
   PubMedGoogle Scholar
• Zia F, Kendall M, Watson SP, Mendes PM. Platelet aggregation induced by polystyrene and platinum nanoparticles is dependent on surface area. RSC Adv. 2018;8(66):37789–37794. doi:10.1039/C8RA07315E30713685
   PubMed Web of Science ®Google Scholar
• Radomski A, Jurasz P, Alonso-Escolano DA, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146(6):882–893. doi:10.1038/sj.bjp.070633316158070
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Patri AK, SImak J, et al. Nanopartcile size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm. 2012;9(3):382–3923. doi:10.1021/mp200463e22026635
   PubMed Web of Science ®Google Scholar
• Frohlich E. Action of nanoparticles on platelet activation and plasmatic coagulation. Curr Med Chem. 2016;23(5):408–430. doi:10.2174/092986732366616010615142826063498
   PubMedGoogle Scholar
• Grant RA, Zucker MB. EDTA-induced increase in surface charge associated with the loss of aggregability. Assesment by partition in aqueous two-phase polymer systems and electrophoretic mobility. Blood. 1978;52:515–523.98183
   PubMed Web of Science ®Google Scholar
• Kälvegren H, Jönsson S, Jonasson L. Release of matrix metalloproteinases-1 and −2, but not −9, from activated platelets measured by enzyme-linked immunosorbent assay. Platelets. 2011;22(8):572–578. doi:10.3109/09537104.2011.58330021756063
   PubMed Web of Science ®Google Scholar
• Gresele P, Falcinelli E, Loffredo F, et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J. 2011;32(3):316–325. doi:10.1093/eurheartj/ehq39021036774
   PubMedGoogle Scholar
• Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med. 2009;206(11):2365–2379. doi:10.1084/jem.2009068719808257
   PubMed Web of Science ®Google Scholar
• Galt SW, Lindemann S, Allen L. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res. 2002;90(10):1093–1099. doi:10.1161/01.res.0000022879.57270.1112039799
   PubMedGoogle Scholar
• Kuliczkowski W, Radomski M, Gąsior M, et al. MMP-2, MMP-9, and TIMP-4 and response to aspirin in diabetic and nondiabetic patients with stable coronary artery disease: a pilot study. Biomed Res Int. 2017;2017:9352015. doi:10.1155/2017/935201528770228
   PubMedGoogle Scholar
• Falcinelli E, Giannini S, Boschetti E, Gresele P. Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. Br J Haematol. 2007;138(2):221–230. doi:10.1111/j.1365-2141.2007.06635.x17593030
   PubMedGoogle Scholar
• Hosseinzadegan H, Tafti D. Mechanisms of platelet activation, adhesion and aggregation. Thromb Haemost Res. 2017;1(2):1008.
   Google Scholar
• Espinosa EVP, Murad JP, Khasawneh FT. Aspirin: pharmacology and clinical applications. Thrombosis. 2012;2012:173124.22195279
   PubMedGoogle Scholar
• Choi WS, Jeon OH, Kim HH, Kim DS. MMP-2 regulates human platelet activation by interacting with integrin alphaIIbbeta3. J Thromb Haemost. 2008;6(3):517–523. doi:10.1111/j.1538-7836.2007.02871.x18088350
   PubMedGoogle Scholar
• Sang QX, Jin Y, Newcomer RG, et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem. 2006;6(4):289–316. doi:10.2174/15680260677628704516611144
   PubMedGoogle Scholar
• Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015;35(1):24–29. doi:10.1161/ATVBAHA.114.30341125256236
   PubMed Web of Science ®Google Scholar
• Stang K, Krajewski S, Neumann B, et al. Hemocopatibilty testing according to ISO 10993-4: discrimination between pyrogen- and device-induced hemostatic activation. Mater Sci Eng C Mater Biol Appl. 2014;42:422–428. doi:10.1016/j.msec.2014.05.07025063137
   PubMedGoogle Scholar
• Fang W, Chi Z, Li W, Zhang X, Zhang Q. Comparative study on the toxic mechanisms of medical nanosilver and silver ions on the antioxidant system of erythrocytes: from the aspects of antioxidant enzyme activities and molecular interaction mechanisms. J Nanobiotechnology. 2019;17:66. doi:10.1186/s12951-019-0502-231101056
   PubMed Web of Science ®Google Scholar
• Muller L, Steiner SK, Rodriguez-Lorenzo L, Petri-Fink A, Rothen-Rutishuaser B, Latzin P. Exposure to silver nanoparticles affects viability and function of natural killer cells, mostly via the relase of ions. Cell Biol Toxicol. 2018;34:167–176. doi:10.1007/s10565-017-9403-z28721573
   PubMed Web of Science ®Google Scholar
• Wojnicki M, Luty-Błocho M, Kotańska M, et al. Novel and effective synthesis protocol of AgNps functionalized using L-cysteine as a potential drug carrier. Naunyn Schmiedebergers Arch Pharmacol. 2018;391(2):123–130. doi:10.1007/s00210-017-1440-x
   PubMed Web of Science ®Google Scholar
• Ferrer MCC, Eckmann UN, Composto RJ, Eckmann DM. Hemocompatibility and biocompatibility of antibacterial biomimetic hybrid films. Toxicol Appl Pharmacol. 2013;272(3):703–712. doi:10.1016/j.taap.2013.07.02323933530
   PubMedGoogle Scholar
• Huang H, Lai W, Cui M, et al. An evaluation of blood compatibility of silver nanoparticles. Sci Rep. 2016;6:25518. doi:10.1038/srep2551827145858
   PubMed Web of Science ®Google Scholar
• Mirshafiee V, Jiang W, Sun B, Wang X, Xia T. Facilating translational nanomedicine via predictive safety assessment. Mol Ther. 2017;25(7):1522–1530. doi:10.1016/j.ymthe.2016.10.00428412168
   PubMedGoogle Scholar